This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
There are pharma companies on the list, including Kymab , which at number 87 is working with the Bill & Melinda Gates Foundation to test several potential vaccines. Seventy-seven firms on this year’s list were funded by venture capital or angel investors, compared with 41 in the first year.
In 1990, the US Food and Drug Administration (FDA) requested Astra to change Losec’s brand name to Prilosec, to avoid confusion with Sanofi-Aventis’ diuretic, Lasix (furosemide). In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune, buying its drug-development pipeline for $15.2
Viatris is seeking FDA approval to market generic versions of both Januvia and Janumet in the US. The two judgments are a big victory for Merck, given that Januvia remains its third best-selling product after cancer immunotherapy Keytruda (pembrolizumab) and HPV vaccine Gardasil, with sales of almost $2.5 The US patent (No.
The global health crisis caused spending on healthcare to increase , due to the funding provided to the development and purchases of vaccines and treatments, as well as support provided for the associated infrastructure. The short story so far.
The interaction is severe enough that prescribing information for many NSAIDs warns against the concomitant use of corticosteroids in a Food and Drug Administration (FDA) issued Medication Guide. Still, they are independently associated with many significant side effects, much so that the FDA has issued guidance regarding their use.
Its subsidiary, DePuy's CHARITE Artificial Disc for degenerative disc disease was the first device to be approved by the US FDA By acquiring Roche’s OTC business, Bayer was able to strengthen its consumer health business. by the sales of Humira 2006 Johnson & Johnson recorded global sales of $53.3B
In Aug’21, the US FDA cleared QSam’s IND application for CycloSam. In Jun’21, the company initiated the evaluation of FAP-2286 in a P-I/II clinical trial (LuMIERE) following the US FDA’s IND clearance. In Sep’21, the US FDA granted DUNP19 an ODD for Osteosarcoma.
Sanofi Pumps $554M into New Vaccine Manufacturing Facility in Eastern France.” www.fiercepharma.com/manufacturing/sanofi-pumps-554m-into-new-vaccine-manufacturing-facility-eastern-france 41 Boccard. New Project: Evolutive Vaccines Facility for Sanofi.” www.boccard.com/evolutive-vaccines-facility-for-sanofi/ 42 Amgen.
With the current lapse in authorization, FDA may only award RPD PRVs for applications that have received an RPD designation before December 20, 2024, andunless reauthorized before thenmay not award any RPD PRVs after September 30, 2026. Below, we discuss some of its downstream impacts on the PRV landscape. See Table 1.
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA. EMA/CHMP/ICH/24235/2006. Internet] Vaccines Europe. Pharmaceutics. 2021; 13(1): 48. ICH Q8(R2) Pharmaceutical Development – Scientific Guideline. 22 June 2017. EMA/CHMP/ICH/167068/2004. 3 February 2023. J Pharm Sci. 2024; 113: 837-855.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content